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ttp://dx.doi.org/10.1016/j.ajpath.2012.09.024Biologically accurate mouse models of human cancer have become important tools for the study of human
disease. The anatomical location of various target organs, such as brain, pancreas, and prostate, makes
determination of disease status difﬁcult. Imagingmodalities, such asmagnetic resonance imaging, can greatly
enhancediagnosis, and longitudinal imagingof tumorprogression is an important source of experimental data.
Even inmodels where the tumors arise in areas that permit visual determination of tumorigenesis, longitudinal
anatomical and functional imagingcanenhance the scopeof studiesby facilitating theassessmentofbiological
alterations, (such as changes in angiogenesis, metabolism, cellular invasion) as well as tissue perfusion and
diffusion. One of the challenges in preclinical imaging is the development of infrastructural platforms required
for integrating in vivo imagingand therapeutic responsedatawith ex vivopathological andmolecular datausing
a more systems-based multiscale modeling approach. Further challenges exist in integrating these data for
computational modeling to better understand the pathobiology of cancer and to better affect its cure. We
review the current applications of preclinical imaging and discuss the implications of applying functional
imaging tovisualize cancerprogressionand treatment. Finally,weprovidenewdata fromanongoingpreclinical
drug study demonstrating howmultiscalemodeling can lead to amore comprehensive understanding of cancer
biology and therapy. (Am J Pathol 2013, 182: 312e318; http://dx.doi.org/10.1016/j.ajpath.2012.09.024)This work was supported by NIH grants R01CA129003 (C.A.),
P30CA51008 (L.W.), HHSN2612200800001E (R.C., S.M. and Y.W.), the
in Silico Center for Research Excellence (ISRCE) (R.C., S.M. and Y.W.),
the Advance Brain Cancer Cure Foundation (C.A.) and the College of
Science at George Mason University (E.F.P.).
This article is part of a review series on imaging in small animal models.The extensive pharmacological studies that have been aimed
at developing and testing new anti-neoplastic compounds
have clearly established the need for both highly accurate
preclinical models, as well as the methods to longitudinally
assess therapeutic response. These translational studies havestigative Pathology.
.
Preclinical Imaging and Systems Biologydriven signiﬁcant technological advances in both anatomical
and functional imaging and have resulted in the engineering
of small animal imaging platforms, including luminescence,
ﬂuorescence, positron emission tomography, and magnetic
resonance imaging (MRI). Currently, signiﬁcant needs exist
related to enhancing our ability to use quantitative anatom-
ical, metabolic, and functional imaging, integrated into
a systems approach to clinical medicine, to expand our
understanding of cancer biology and to identify early
markers of effective therapeutic intervention.
Mouse Models
Genetically engineered (GE) mice, since their introduction
more than 30 years ago, have become increasingly important
to our understanding of the interrelationship between genes,
the organism, its environment, and the efﬁcacy of new and
existing treatment régimes. The early GE models were
relatively simple, primarily relying on the integration of
a promoter and transgene into the mouse genome, although
technological advances such as inducible gene expression
(eg, tetracycline, tamoxifen, or steroid hormones) and the
Cre:LoxP gene ablation/modiﬁcation systems have lead to
more biologically relevant models with increased ﬁdelity to
the cellular and molecular basis for many human cancers.1 In
fact, the use of GE mice and xeno- and allo-grafting models
have become the hallmark of translational platforms for the
study of human cancers and their treatment.
Imaging
There are inherent difﬁculties associated with many GE
models (eg, brain,2 prostate,3 and gastric4), as in humans, in
identifying disease initiation, its progression, and its treatment
without invasive surgery or sacriﬁcing the animal. Preclinical
imaging modalities have been developed to overcome these
limitations and to enable longitudinal studies analogous to
clinical imaging and trials. Two of these preclinical imaging
modalities (ie, MRI and positron emission tomography) allow
for functional and metabolic imaging. Importantly, MRI is
unique in its ability to combine high resolution anatomical
imaging with functional and metabolic analyses, making it
one of themost ﬂexible preclinical/clinical imaging platforms.
Need for Informatics and Systems Biology to Complete
the Multiscale Investigational Platform in Cancer
Imaging data can both deﬁne the location of deep tissue
tumors and provide data related to cancer progression and
regression (response to therapy), because many longitudinal
preclinical studies seek to combine in vivo imaging data with
ex vivo pathology, as well as with genetic and molecular
changes within the target tissue to quantify complex pheno-
typic traits. The complexity of the data generated, however,
which by necessity must include those of the underlyingThe American Journal of Pathology - ajp.amjpathol.orgmodel, requires cross-platform multiscale approaches. These
platforms, by deﬁnition, must integrate the imaging data for
a region of interest (eg, a tumor), which occurs at the
organismal and macroscopic scales, with the data from the
cellular or microscopic scale (eg, pathology, vascularity) and
with data derived at the subcellular or molecular scale (eg,
mRNA, proteomics, metabolomics). Currently, there are
National Institutes of Health initiatives such as the cancer
Biomedical Informatics Grid, and National Cancer Institute
initiatives such as The Cancer Genome Atlas that seek to
support the groundwork collaborations between cancer
imaging laboratories and molecular and bioinformatics/
bioengineering groups that are needed to develop these
capabilities. Additional innovations, such as the Georgetown
Database of Cancer (G-DOC), a systems medicine data
integration, analysis, and visualization platform,5 will even-
tually allow for real-time data analysis. These bioinformatics
platforms will allow for correlative data comparisons, such as
those available from The Cancer Genome Atlas, and for
target validation, as well as for predictive modeling of tumors
and their responses to intervention.
In this review, recent advances in the use of MRI in
preclinical cancer research are highlighted, and we discuss and
give an example of the central role that MRI combined with
systems biology can fulﬁll in imaging-based preclinical studies.
Tumor Imaging
Ultrasound and Computed Tomography
Many outstanding imaging modalities exist for anatomical
imaging (eg, ultrasound was one of the earliest translations
of human imaging into preclinical modeling). Ultrasound
provides a rapid and sensitive method for the identiﬁcation of
changes in skin architecture, volumetric analyses of surface
tumors, such as xenografted human cancer cells, oncogene-
induced changes in the mammary gland before palpable
tumors arise,6 and vascular bloodﬂowbyDoppler. Ultrasound
is limited to some extent by its depth of imaging, its dynamic
range, and its lack of contrast in some tissues, and also by its
inability to perform functional and metabolic imaging. Simi-
larly, computed tomography iswidely used in both clinical and
preclinical settings and provides extremely high resolution
anatomical imaging, however, the use of computed tomog-
raphy is limited in its metabolic and functional imaging as
a stand-alone modality. Furthermore, computed tomography
involves ionizing radiation exposure necessitating judicious
use in both research and diagnostic settings.
MRI
MRI has long been used for anatomical imaging to allow the
visualization of changes that occur during disease prog-
ression. In addition, magnetic resonance-based chemical
imaging using hyperpolarized carbon-14 has shown great
promise in visualizing alterations in tissue pH7 and cellular
redox activity,8 and proton magnetic resonance spectroscopy
(1H-MRS) is a rapidly developing ﬁeld of discovery,313
Albanese et alenabling the measurement of altered energy and metabolic
pathways in situ. In combination with anatomical MRI, for
example, the measurement of changes in citrate to choline
ratios by 1H-MRS have identiﬁed cancerous areas of the
human prostate.9 Using 1H-MRS, we found that the GE mice
we developed that presented with spontaneous prostate
cancer, also exhibited an altered choline-to-citrate proﬁle,
which was seen in humans.3 These data served to further
validate mice as a biologically relevant model amenable to
preclinical studies with translational impact on the clinical
prostate disease. Importantly, identifying metabolic changes
that correlate with cancer progression allows for a possibility
of monitoring intervention through dynamic monitoring of
tumor chemistry in vivo.
The recent application of functional magnetic resonance
pulse sequences to cancer is also beginning to enhance the
noninvasive preclinical and clinical diagnostic accuracy and
monitoring of disease progression and treatment efﬁcacy of a
number of neoplasms, including those of the brain, prostate,
and breast. Diffusion-weighted imaging takes advantage of
altered localized diffusion of water in tissue and is being
actively supported by the National Cancer Institute as a
noninvasive technique for imaging cancer biomarkers.10
Diffusion tensor imaging can identify differences in direc-
tional diffusion (anisotropy), for example, between white-
matter tracts and nearby malignant tumors. Perfusion-
weighted imaging estimates the rate of regional blood ﬂow,
which is higher in regions with higher metabolic demands,
and regional blood volume, which is an indirect marker of
angiogenesis.11 Susceptibility-weighted imaging uses velo-
city compensated, radio frequency-spoiled, high-resolution,
three-dimensional gradient echocardiography scans. With
susceptibility-weighted imaging, signals from substances
with different susceptibilities, such as tissue-fat, tissue-tumor,
and tissue-water interfaces will become out of phase,
enhancing their boundaries.12 Hori et al13 have noted that the
ability to detect these changes in the tumor can lead to better
volume recognition and tissue segmentation, helping to
identify smaller structures and delineate vascular and micro-
vascular lesions. Dynamic contrast-enhanced (DCE)-MRI
provides a noninvasive method for evaluating tumor vascu-
lature patterns based on contrast accumulation andwashout.14
DCE-MRI can potentially identify intratumoral heterogeneity
of vascular permeability reﬂecting tumor angiogenic activity.
We predict that both spectroscopic and functional/diffusion
imaging hold great promise for visualizing responses to both
chemical and radiological therapies, nearly in real time.Data Integration, Bioinformatics, and Systems
Biology
High-throughput discovery technologies, such as next-
generation sequencing, and the core -omics, such as geno-
mics, transcriptomics, proteomics, and metabolomics, have
furthered our understanding of cancer initiation and314progression. In addition, these approaches have helped to
deﬁne diagnostic and mechanistic biomarkers, as well as
establishing the signaling network rewiring that occurs
during tumorigenesis. Most of these studies, however, are
performed on excised tumor tissue making them static
studies, which are unable to reﬂect the dynamic changes that
occur during therapeutic intervention. To overcome these
limitations, computational models of disease are essential to
allow for the prediction of disease progression and/or
responses to treatment with time. The integration of the
static ex vivo data with imaging and the dynamic informa-
tion from imaging will help to build these models, however,
before model building, careful integration of the various
forms of data (ie, the -omics, pathology, and/or imaging)
and the subsequent knowledge extraction are necessary.
Computational Platforms for the Integration of
Molecular, Clinical, and Imaging Data
As previously discussed, a promising new area of cancer
research is the integration of image features (eg, shape, size,
metabolism, perfusion) and molecular data (eg, gene
expression, gene copy number, microRNA, metabolomics).
Furthermore, once fully validated, the in-depth under-
standing of the molecular characteristics underlying image
features may result in their use as predictive markers of
prognosis and therapeutic response. In the future, these
features may also be incorporated into clinical decision-
making, which would enhance patient treatment and care.
Currently, the imaging-based oncological decision-
making used in assessing responses to chemotherapy is based
primarily on changes in tumor size. This approach, although
useful, has limitations for predicting recurrence and assess-
ment of minimal residual disease. Imaging platforms, such
as combining positron emission tomography with either
computed tomography orMRI, can offer a more accurate view
of response to therapy at the cellular level by assessing diverse
aspects of the tumor and its environment, including tumor
metabolic activity, tissue vascularity, cellular apoptosis,
growth factor levels, and blood oxygenation to name a few.
This functional information can be more effective than
conventional anatomical imaging alone for identifying early
responses to therapy and may ultimately provide the necessary
clinical information so that less effective therapies can be
stopped earlier. Such studies will havemultiple data points that
need to be integrated in a uniﬁed system that can process results
from multiple studies.
Three independent examples of platforms being built for
the purpose of integrating disparate data include the Infor-
mation Sciences in Imaging group at Stanford, the Investi-
gation of Serial Studies to Predict Your Therapeutic Response
With Imaging and Molecular Analysis 1 and 2 trials, and the
G-DOC. The Information Sciences in Imaging group is
developing several tools to collect and integrate annotated
imaging to clinical and molecular data through novel
computational models. One such tool is the Electronicajp.amjpathol.org - The American Journal of Pathology
Preclinical Imaging and Systems BiologyPhysician Annotation Device, which is an open source tool
enabling researchers and clinicians to identify and quantify
imaging biomarkers. The Investigation of Serial Studies to
Predict Your Therapeutic Response With Imaging and
Molecular Analysis 1 was a collaboration of the American
College of Radiology Imaging Network, Cancer and
Leukemia Group B, and the National Cancer Institute’s
Specialized Programs of Research Excellence. This study was
initiated to identify the molecular markers of response to
conventional neoadjuvant chemotherapy, as well as the
imaging markers associated with response to therapy.15 The
G-DOC, developed at Georgetown University, is a tool that
currently contains various types of -omics data integrated with
clinical metadata and patient outcome data. This promising
new model for the storage, integration, and visualization of
multiple disparate data types is described as follows.
It is clear that one of the major challenges in analyzing
the large and complex datasets generated by the various
integrative platforms is making them available, and more
importantly useful, to the end user, whether it is for the
clinical caregiver or the translational research ﬁeld as
a whole. For example, the generation of reports capable of
positively impacting clinical care will require a signiﬁcantly
ﬁltered and reduced set of data points to be useful to
a physician who will be making critical decisions regarding
how to best treat their patients based on the newest infor-
mation available. We designed the G-DOC as both
a cutting-edge data integration platform and as an integra-
tive knowledge discovery system for oncology and trans-
lational research communities. The goal of the G-DOC is to
provide cancer researchers with a broad range of tools for
data reduction, visualization, and analysis.5 In addition, the
G-DOC includes manually curated information on small
molecules as potential drug candidates for key biomarkers/
target proteins. The G-DOC further supports ﬂexible clinical
criteria browsing to enable selection of speciﬁc patient
cohorts, and it facilitates the generation of detailed reports
and informative publication-quality plots. Internal chemical
compound libraries can be screened easily using the inte-
grated structure and detailed molecular property search
functions, with the goal of identifying new therapeutic
candidate molecules.
The G-DOC also allows researchers to securely share
knowledge with others through a powerful suite of
collaboration-enabling features operating within its secure
environment, and the G-DOC supports computationally
intensive, high memory-using tasks, such as class compar-
ison, hierarchical clustering, principal component analysis,
and network analysis for transcriptomic, genomic, and
metabolomic data. The G-DOC is constantly being updated,
including our current modiﬁcations that allow for the inte-
gration of imaging data. By providing a powerful but easy-
to-use interface, the G-DOC is intended speciﬁcally to
address the activation barrier normally encountered by
basic, clinical, and translational researchers when trying to
make use of biomedical informatics tools.The American Journal of Pathology - ajp.amjpathol.orgDetection of Topological Changes in Biological
Network between Phenotypes
Gene regulatory networks are both context-speciﬁc and
dynamic in nature. With different conditions, diverse regula-
tory components and mechanisms can be activated or
repressed, leading to rewired genetic and signaling networks
and topological changes. For example, a deviation from the-
normal regulatory network topology may reveal the mecha-
nism of tumorigenesis,16 and the pathways that are involved
may serve as biomarkers or drug targets.17,18 The differential
dependency network is a graphical, model-based analytical
tool for detecting and visualizing statistically signiﬁcant
topological changes in dependency networks.19,20 As an
integrated component of the G-DOC, the differential depen-
dency network can be applied to different tissue types,
including normal versus tumor, different cancer subtypes,
drug sensitive versus insensitive tumors, as well as the
differences in pathways targeted by different drugs or drug
combinations, accurately capturing the topological changes of
the network.
Multiclass Biomarker Selection for Studying
Heterogeneous Cancers
Multiclass gene selection is an imperative task for identi-
fying phenotype-associated mechanistic genes and achie-
ving accurate diagnostic classiﬁcations.21,22 The Phenotypic
Up-regulated Gene Support Vector Machine is a cancer
biomedical informatics grid analytical tool for multiclass gene
selection and classiﬁcation.23 The Phenotypic Up-regulated
Gene Support Vector Machine provides a simple yet accu-
rate strategy to identify statistically reproducible mechanistic
marker genes for the characterization of heterogeneous
cancers. Multiscale preclinical modeling of cancer progres-
sion and treatment with vector machines such as the Pheno-
typic Up-regulated Gene Support Vector Machine will be
necessary to begin to understand the mechanisms underlying
tumor regression, after apparently successful interventional
therapy and the possible roles that are played by tumor
heterogeneity.
An Example of MRI and Systems Integration for
Assessment of Drug Efﬁcacy
Medulloblastoma
Childhood brain tumors represent approximately 25% of all
childhood cancers and medulloblastoma (MB) is the most
common childhood brain malignancy, accounting for 25% of
these tumors.24 Four consensus subtypes of MB have been
molecularly deﬁned based on gene expression patterns and
chromosomal abnormalities.25e27 MBs are highly malignant,
poorly differentiated tumors that have a propensity to spread
throughout the neuraxis, either early in the course of the illness
or with disease recurrence. Immediately after surgical removal315
Albanese et alof the tumor, radiotherapy to the entire brain and spine
(craniospinal irradiation) is administered and is followed by
nine months of multi-agent chemotherapy. For standard risk
MB, the ﬁve-year survival rate approaches 80%. In high-risk
MB, which is classiﬁed by patient age, histological/molecular
features, postoperative residual disease, and/or the presence
of metastatic disease, survival rates range from 20% to 60%,
with signiﬁcantly more morbidity from intensiﬁed radiation
and chemotherapy. Unfortunately, the majority of all MB
survivors are left with auditory, neuroendocrine, and neuro-
cognitive deﬁcits that can severely affect employability and
social achievement.28 It must also be noted that radiation is
avoided in children less than three years of age due to its
destructive effects on the developing nervous system,
confounding effective treatment in the youngest patients. The
long-term prognosis for most of these children is dismal.
The ability to predict which cases will ultimately
experience disease recurrence despite therapy is the ﬁrst
step in improving the therapeutic index of existing ther-
apies. Recently, progress has been made toward the
molecular classiﬁcation of medulloblastoma subtypes with
prognostic implications. Historically, therapeutic intensi-
ﬁcation has been the only strategy to address the high-risk
disease strata. The unfortunate consequence of this has
been signiﬁcantly more toxicity with only marginally
better outcomes.
Rationally designed, molecularly targeted therapies,
which are based on the underpinnings of preclinical and
clinical biological discovery, hold the promise for exploiting
the tumor altered networks to provide effective therapy.
Such an approach will require clinical trial testing based on
a different framework than that developed for cytotoxic
therapies due to the fact that cell death resulting in tumor
shrinkage will no longer be the only potential positiveFigure 1 Preclinica
spectra of the ND2-Smo
ment used to acquire
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(Cho) in normal mouse
MB metabolite ratios af
week) of pharmacologi
Differential dependent
on samples of normal
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316outcome of a successful drug. A molecularly targeted agent
must be judged on its ability to reach the anatomical loca-
tion of the tumor, maintain effective dosage levels, effect the
molecular change for which it was designed, and bring forth
the desired change in tumor cell phenotype, for example
growth arrest, apoptosis, anti-angiogenesis, or loss of
invasion, while minimizing off-target cytotoxicity. The
assessment of these outcomes will require more than
conventional anatomical imaging; it will require a systems
biology-based approach that combines functional imaging
with biomarker quantiﬁcation in a platform capable of
providing a real-time assessment of disease state. Paradox-
ically, the effort to reduce therapy for patients with a better
prognostic class of disease may entail the risk of increasing
disease recurrence in comparison with those rates achieved
with potentially excessive therapy. The scaling back of
treatment, while still maintaining patient safety, will require
the ability to monitor therapeutic efﬁcacy serially and in real
time to identify members of the group whose disease is not
responding as expected, in effect creating a stopping rule.
Anatomical and functional imaging combined with
biomarker quantiﬁcation holds the promise of creating such
a platform.
MRI as a Diagnostic Platform
The development and testing of such a systems-based
approach to drug validation for treating MB is not feasible
using human subjects in the early stages; animal models
exist that faithfully recapitulate childhood MB. In an
end-point study using MRI as a diagnostic platform, we
recently established that arsenic trioxide, a Food and Drug
Administration-approved, second-line therapeutic used for
the treatment of acute promyelocytic leukemia, was effectivel imaging drug responses in the ND2-SmoA1 mouse. A: 1H-MRS
A1 medulloblastoma; insert, MRI of the tumor and voxel place-
the spectra. B: 1H-MRS metabolite ratios of n-acetylaspartate
), creatine (Cre), lactate (Lac), and taurine (Tau) versus choline
cerebellum and ND2-SmoA1 medulloblastomas. C: Alterations in
ter treatment with subclincial doses (0.15 mg/kg three times per
cal grade arsenic trioxide (ATO) versus control-treated mice. D:
network modeling of reverse phase protein microarray performed
cerebellum versus MB (red) and those of ATO-treated versus
en) collected from the mice in panels AeC.
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MB.2 Longitudinal anatomical imaging studies have now
been performed on control and ND2-SmoA1 mice using our
7T Bruker MRI, and 1H-MRS was also performed using
a localized point resolved spectroscopy sequence as previ-
ously described1,29,30 (Figure 1A). The metabolite ratios of
normal andMB tissueswere established (Figure 1B), showing
that altered ratios of choline to n-acetylaspartate, choline to
creatine, choline to taurine, and choline to myoinositol were
associated with MB, correlating well with previous studies
performed in this model.31 A representative comparison of the
spectra of tumor-bearing ND2-SmoA1 mice after treatment
with arsenic trioxide versus those of control-treated mice is
shown (Figure 1C). The ratios of thesemetabolites were found
to be dynamic early indicators of tumor targeting by arsenic
trioxide, as some changes were observed before any obvious
changes in tumor growth kinetics were seen (not shown).
Reverse phase protein microarray32,33 was then performed
on small biopsies collected at necropsy to interrogate the
functional protein signaling architecture, and the data were
used to inform our differential dependency network. Using the
pathway activation data acquired by reverse phase protein
microarray from the MB progression versus response-to-drug
experiments, we performed pair-wise and one versus rest
differential network analysis using our differential depen-
dency network modeling tool.19 Our analyses indicated that
signaling networks encompassing the receptor tyrosine
kinases ErbB-2 and insulin-like growth factor receptor
feeding into cell cycle regulators, such as CDK2 and GSK3b,
were perturbed in the tumors versus normal cerebellum
(Figure 1D). After arsenic trioxide treatment, these receptor
signaling pathway lesions were repaired, leading to the re-
establishment of the linkage to cell cycle regulation and
apoptosis (Figure 1D).Conclusion and Future Directions
Much has been accomplished with respect to integrating
functional and metabolic imaging into preclinical and clinical
studies, although much remains to be done. Currently, plat-
forms such as the G-DOC provide the means by which
existing and emerging -omics data can be interrogated to
improve the diagnostics and outcome, both experimentally
and for individual cancer patients. Ultimately, it is important
to seamlessly combine in vivo imaging-based data associated
with tumor progression and/or regression (regardless of
the imaging modality), with both ex vivo pathological
examinations performed on tissue samples as well as patient
outcomes. In addition, the exciting new methodology that
was recently developed allows for the continuous culturing of
a patient’s own normal and malignant epithelial cells, termed
conditionally reprogrammed cells,34,35 adds yet another
powerful approach to cancer research and discovery. The
long-term vision for implementing systems-based integration
of multimodal imaging and -omics information, performedThe American Journal of Pathology - ajp.amjpathol.orgon matched normal and malignant tissues, requires the
establishment of robust and comprehensive informatics
platforms that will support hypothesis generation and
hypothesis testing to positively impact both cancer research
and its clinical practice. Continued collaborative efforts
between cancer researchers and clinicians, imaging experts,
drug discovery programs, and computational scientists are
essential.Acknowledgments
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